The development of PARP inhibitors in ovarian cancer: from bench to bedside

被引：40

作者：

Drew, Yvette ^{[1
,2
]}

机构：

[1] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England

来源：

BRITISH JOURNAL OF CANCER | 2015年 / 113卷

关键词：

olaparib; PARP; ovarian cancer; STRAND BREAK REPAIR; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; SUSCEPTIBILITY GENE BRCA1; RANDOMIZED PHASE-2 TRIAL; HOMOLOGOUS RECOMBINATION; MUTATION CARRIERS; DNA; CELLS; THERAPY; MAINTENANCE;

D O I：

10.1038/bjc.2015.394

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The nuclear enzyme poly (ADP-ribose) polymerase (PARP) represents an important novel target in the treatment of ovarian cancer. This article charts over 50 years of research from the discovery of the first PARP enzyme in 1963, to the approval and licensing in 2015 of the first PARP inhibitor, olaparib (Lynparza), in the treatment of BRCA-mutated ovarian cancer.

引用

页码：S3 / S9

页数：7

共 69 条

[1] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[2] Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition [J].

Audeh, M. William .

PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 :307-316

[3] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].

Audeh, M. William ;

Carmichael, James ;

Penson, Richard T. ;

Friedlander, Michael ;

Powell, Bethan ;

Bell-McGuinn, Katherine M. ;

Scott, Clare ;

Weitzel, Jeffrey N. ;

Oaknin, Ana ;

Loman, Niklas ;

Lu, Karen ;

Schmutzler, Rita K. ;

Matulonis, Ursula ;

Wickens, Mark ;

Tutt, Andrew .

LANCET, 2010, 376 (9737) :245-251

[4] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[5]

BENJAMIN RC, 1980, J BIOL CHEM, V255, P493

[6] The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin [J].

Bhattacharyya, A ;

Ear, US ;

Koller, BH ;

Weichselbaum, RR ;

Bishop, DK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) :23899-23903

[7] Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer [J].

Bolton, Kelly L. ;

Chenevix-Trench, Georgia ;

Goh, Cindy ;

Sadetzki, Siegal ;

Ramus, Susan J. ;

Karlan, Beth Y. ;

Lambrechts, Diether ;

Despierre, Evelyn ;

Barrowdale, Daniel ;

McGuffog, Lesley ;

Healey, Sue ;

Easton, Douglas F. ;

Sinilnikova, Olga ;

Benitez, Javier ;

Garcia, Maria J. ;

Neuhausen, Susan ;

Gail, Mitchell H. ;

Hartge, Patricia ;

Peock, Susan ;

Frost, Debra ;

Evans, Gareth ;

Eeles, Rosalind ;

Godwin, Andrew K. ;

Daly, Mary B. ;

Kwong, Ava ;

Ma, Edmond S. K. ;

Lazaro, Conxi ;

Blanco, Ignacio ;

Montagna, Marco ;

D'Andrea, Emma ;

Nicoletto, Maria Ornella ;

Johnatty, Sharon E. ;

Krueger, Susanne ;

Jensen, Allan ;

Hogdall, Estrid ;

Goode, Ellen L. ;

Fridley, Brooke L. ;

Loud, Jennifer T. ;

Greene, Mark H. ;

Mai, Phuong L. ;

Chetrit, Angela ;

Lubin, Flora ;

Hirsh-Yechezkel, Galit ;

Glendon, Gord ;

Andrulis, Irene L. ;

Toland, Amanda E. ;

Senter, Leigha ;

Gore, Martin E. ;

Gourley, Charlie ;

Michie, Caroline O. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04) :382-390

[8] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[9] PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination [J].

Bryant, Helen E. ;

Petermann, Eva ;

Schultz, Niklas ;

Jemth, Ann-Sofie ;

Loseva, Olga ;

Issaeva, Natalia ;

Johansson, Fredrik ;

Fernandez, Serena ;

McGlynn, Peter ;

Helleday, Thomas .

EMBO JOURNAL, 2009, 28 (17) :2601-2615

[10] Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination [J].

Buisson, Remi ;

Dion-Cote, Anne-Marie ;

Coulombe, Yan ;

Launay, Helene ;

Cai, Hong ;

Stasiak, Alicja Z. ;

Stasiak, Andrzej ;

Xia, Bing ;

Masson, Jean-Yves .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2010, 17 (10) :1247-+

← 1 2 3 4 5 6 7 →